Evolent Health

Evolent Health, Inc. engages in the provision of health care delivery and payment services. It deals with population health management, health plan and third party administration, network performance and pharmacy benefit management, risk adjustment, analytics and performance improvement, and technology and electronic medical record integration. The firm operates through Services and True Health segments. The Services segment includes clinical and administrative solutions such as total cost of care management and specialty care management and comprehensive health plan administrative services. The True Health segment offers a physician-led health plan for employer-sponsored health coverage. The company was founded by Frank J. Williams, Seth B. Blackley, and Thomas Peterson III in August 2011 and is headquartered in Arlington, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Evolent Health excels in Q4 2022, eyes growth with Humana

Evolent Health posts strong financials, exceeding revenue and EBITDA targets.
Strategic partnerships and focus on organic growth drive value creation.
Challenges lie in maintaining growth momentum and effective execution.
Opportunities include margin expansion, capital optimization, and Humana partnerships.

Evolent Health surpasses Q1 expectations, eyes revenue growth opportunities

Evolent Health's Q1 performance exceeded expectations, driven by strong revenue growth and margin expansion initiatives. While facing challenges like revenue adjustments and Medicaid rebates, the company remains focused on capitalizing on growth opportunities through strategic partnerships and operational efficiencies.

Evolent Health excels in Q2, eyes $300M EBITDA target

Evolent Health's robust performance in Q2, strategic partnerships, and focus on organic growth position it well to achieve its financial targets.
Challenges lie in Medicaid membership declines, capital allocation optimization, and refinancing decisions amidst market uncertainties.
Opportunities in patient-centric care, CMS changes, and integrated entity approach offer avenues for growth and differentiation in the market.

Evolent Health surpasses Q3 expectations, eyes growth in specialty care

Evolent Health's Q3 performance exceeded expectations, driven by strong revenue growth and profitability, underpinned by strategic partnerships and a unique care model.
Despite challenges in ramping up Performance Suite adoption and maintaining cost control, the company's focus on growth and value creation positions it well for future success.
Opportunities in expanding specialty offerings and leveraging new partnerships highlight Evolent's growth potential and commitment to delivering value in the healthcare sector.

Evolent Health exceeds 2023 targets, eyes growth through partnerships

Evolent Health delivered strong financial results in Q4 2023, surpassing its 2023 targets and setting ambitious goals for 2024, driven by Specialty Care offerings and new revenue agreements.
While facing challenges related to medical utilization and new product launches, the company remains focused on organic growth and profitability, supported by a strategic approach to expansion.
Opportunities in cross-selling, new state expansions, and imaging capabilities position Evolent Health for continued growth and revenue diversification in the healthcare sector.

Evolent Health reports robust Q1 earnings, eyes margin improvements

Evolent Health's Q1 performance showcased strong revenue growth and EBITDA in line with guidance.
The company is optimistic about margin improvements, revenue expansion, and maintaining a balanced pipeline.
Challenges include margin impact from new go-lives and ongoing payer negotiations amid cost pressures.
Opportunities lie in improving gross margins, leveraging population changes, and focusing on cash flow expectations.

Evolent Health reports robust Q2 earnings, eyes growth opportunities ahead

Evolent Health's Q2 2024 earnings call highlighted strong financial performance, strategic initiatives, and a positive outlook for future growth. The company's focus on revenue diversification, margin optimization, and disciplined financial management positions it well for continued success in the evolving healthcare landscape.

Evolent Health revises outlook after Q3 challenges, secures financing

Evolent Health navigated higher medical costs impacting Q3 results, leading to a revised outlook for 2024. Despite challenges in managing expenses and oncology costs, the company remains committed to growth and securing new revenue agreements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Evolent Health, Inc. engages in the provision of healthcare delivery and payment services. It deals with population health management, health plan and third party administration, network performance and pharmacy benefit management, risk adjustment, analytics and performance improvement, and technology and electronic medical record integration. The firm operates through Services and True Health segments. The Services segment includes clinical and administrative solutions such as total cost of care management and specialty care management and comprehensive health plan administrative services. The True Health segment offers a physician-led health plan for employer-sponsored health coverage. The company was founded by Frank J. Williams, Seth B. Blackley, and Thomas Peterson III in August 2011 and is headquartered in Arlington, VA.

Evolent Health (EVH) delivered earnings and revenue surprises of -75.00% and 1.47%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Evolent Health (EVH) Reports Q4 Loss, Tops Revenue Estimates

Central Garden & Pet Company

Daktronics

Why Daktronics, Evolent Health, and Central Garden & Pet Slumped Today

A major contract loss in Kentucky is weighing heavily on the managed-care stock.

Why Evolent Health Shares Are Tanking Today

Investors need to pay close attention to Evolent Health (EVH) stock based on the movements in the options market lately.

Options Traders Expect Huge Moves in Evolent Health (EVH) Stock

The health information services company is optimistic about 2020.

Why Evolent Health Stock Popped Wednesday

Evolent Health's (EVH) CEO Frank Williams on Q2 2019 Results - Earnings Call Transcript

Evolent Health (EVH) delivered earnings and revenue surprises of 40.00% and 1.31%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Evolent Health (EVH) Reports Q3 Loss, Tops Revenue Estimates

Evolent Health (EVH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Evolent Health (EVH) to Report a Decline in Earnings: What to Look Out for

Implied Volatility Surging for Evolent Health (EVH) Stock Options

Encana

Falcon Minerals Corp

Sientra

Vivint Solar

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Big Upside Potential Seen for These 5 Stocks Trading Under $10

Evolent Health, Inc. (EVH) CEO Frank Williams on Q2 2019 Results - Earnings Call Transcript

Earnings Preview: Evolent Health (EVH) Q2 Earnings Expected to Decline

Teladoc

Though it's no small task, here are two companies that are trying to change the way Americans think about their healthcare.

2 Companies Trying to Change U.S. Healthcare

Antero Resources

Kosmos Energy

While Most of Wall Street focuses on large- and mega-cap stocks because they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Goldman Sachs Has 5 Stocks Under $10 To Buy With Massive Upside Potential

AxoGen

Axogen, Evolent Health present appealing opportunities.

Analysts Recommend These 2 Falling Knives.

General Mills

Find out why these stocks stood out in a down market.

Why General Mills, CalAmp, and Evolent Health Slumped Today

Shares nose-dive after the company announces a surprise acquisition. Here's what investors need to know.

Why Evolent Health Is Tanking Today

Evolent Health, Inc. (EVH) CEO Frank Williams on Q1 2019 Results - Earnings Call Transcript

News for Evolent Health Stock (EVH)